S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
NYSE:ENZ

Enzo Biochem (ENZ) Stock Price, News & Analysis

$1.08
-0.05 (-4.42%)
(As of 04/19/2024 ET)
Today's Range
$1.07
$1.12
50-Day Range
$1.12
$1.39
52-Week Range
$1.07
$2.74
Volume
256,550 shs
Average Volume
98,433 shs
Market Capitalization
$55.32 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ENZ stock logo

About Enzo Biochem Stock (NYSE:ENZ)

Enzo Biochem, Inc. develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. It also provides AMPIVIEW in situ hybridization probes for enhanced detection of low expressed targets useful in the growing spatial biology space; reagents and assays for cell and gene therapy research and development; POLYVIEW PLUS Enhanced Immunohistochemistry platform, offers solutions within the area of anatomical pathology through optimized assays; Enhanced Immunoassays, pushing sensitivity to expand immunoassay applications for basic research, bioprocess, and diagnostics; AMPIPROBE, a nucleic acid amplification platform; and Axxora.com, a proven distribution platform for original manufacturers of innovative research reagents. The company's proprietary products and technologies in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry, and small molecule chemistry. It markets its products and services through its direct sales force and a network of distributors. The company was incorporated in 1976 and is headquartered in Farmingdale, New York.

ENZ Stock Price History

ENZ Stock News Headlines

Analyzing Enzo Biochem (NYSE:ENZ) and Fortrea (NASDAQ:FTRE)
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
Enzo Biochem: Fiscal Q2 Earnings Snapshot
Enzo Biochem, Inc.
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
Jim Simons Trims Stake in Enzo Biochem Inc
Enzo Biochem Appoints New CEO and CFO
Enzo Biochem Inc (EZB.SG)
Enzo Biochem Inc ENZ
See More Headlines
Receive ENZ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enzo Biochem and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
10/15/2019
Today
4/19/2024
Next Earnings (Estimated)
6/12/2024
Fiscal Year End
7/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medical laboratories
Sub-Industry
N/A
Employees
179
Year Founded
1976

Profitability

Net Income
$20.29 million
Pretax Margin
-71.07%

Debt

Sales & Book Value

Annual Sales
$32.80 million
Book Value
$1.58 per share

Miscellaneous

Free Float
43,286,000
Market Cap
$55.32 million
Optionable
Optionable
Beta
0.75

Social Links

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

ENZ Stock Analysis - Frequently Asked Questions

How have ENZ shares performed in 2024?

Enzo Biochem's stock was trading at $1.39 on January 1st, 2024. Since then, ENZ stock has decreased by 21.6% and is now trading at $1.09.
View the best growth stocks for 2024 here
.

When is Enzo Biochem's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, June 12th 2024.
View our ENZ earnings forecast
.

How were Enzo Biochem's earnings last quarter?

Enzo Biochem, Inc. (NYSE:ENZ) released its quarterly earnings results on Tuesday, October, 15th. The medical research company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.03. The medical research company earned $20.92 million during the quarter. Enzo Biochem had a negative trailing twelve-month return on equity of 36.71% and a net margin of 99.28%.

What other stocks do shareholders of Enzo Biochem own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Enzo Biochem investors own include OneLife Technologies (OLMM), Gilead Sciences (GILD), OPKO Health (OPK), Teva Pharmaceutical Industries (TEVA), Inovio Pharmaceuticals (INO), AbbVie (ABBV), Pfizer (PFE), Advanced Micro Devices (AMD), Amarin (AMRN) and Micron Technology (MU).

How do I buy shares of Enzo Biochem?

Shares of ENZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:ENZ) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners